Can HRT Cause Hair Loss? What You Need to Know

How Hormones Control the Hair Growth Cycle

Every hair follicle cycles through three phases: anagen (active growth, lasting 2 to 7 years), catagen (regression, about 2 weeks), and telogen (rest and shedding, roughly 3 months). Estrogen directly extends the anagen phase. That is why many women notice thicker hair during pregnancy, when estradiol levels can exceed 3,000 pg/mL.

At menopause, circulating estradiol drops below 30 pg/mL. The shortened anagen phase means more follicles enter telogen simultaneously, producing diffuse thinning across the crown and frontal scalp. A cross-sectional study of 178 postmenopausal women found that 52% reported significant hair loss, with severity correlating to lower serum estradiol concentrations [1]. Androgens act on the same follicles through a different mechanism. Testosterone converts to dihydrotestosterone (DHT) via 5-alpha reductase in the dermal papilla. DHT binds androgen receptors with five times the affinity of testosterone, progressively miniaturizing genetically sensitive follicles [2]. The ratio between protective estrogens and follicle-damaging androgens, not the absolute level of either hormone alone, determines clinical outcome.

Why Some HRT Regimens Protect Hair While Others Trigger Shedding

Not all HRT is the same molecule. Estrogen-only therapy in hysterectomized women almost always supports hair density. The Women's Health Initiative estrogen-alone arm (conjugated equine estrogens 0.625 mg/day, N=10,739) did not report increased alopecia compared to placebo over 6.8 years of follow-up [3].

The picture gets complicated when a progestogen is added. Progestogens exist on a spectrum of androgenic activity. Norethisterone (norethindrone) and levonorgestrel are 19-nortestosterone derivatives. They bind the androgen receptor and can raise free testosterone by lowering sex hormone-binding globulin (SHBG) [4]. A woman who is genetically predisposed to androgenetic alopecia may notice accelerated thinning within the first 3 to 6 months on these agents.

By contrast, micronized progesterone (Prometrium, Utrogestan) has anti-androgenic downstream effects. It competes with 5-alpha reductase, reducing conversion of testosterone to DHT at the follicle level. Dydrogesterone behaves similarly. The Endocrine Society's 2015 position statement noted that micronized progesterone has a more favorable side-effect profile than synthetic progestins for cardiovascular and metabolic outcomes, and clinical experience supports the same distinction for hair [5].

Testosterone Therapy and Hair: Where the Risk Concentrates

Testosterone is prescribed to some postmenopausal women for low libido. The Global Consensus Position Statement on testosterone therapy for women, published in 2019 and endorsed by multiple international societies, recommended transdermal testosterone at doses approximating 5 mg/day to restore premenopausal physiological levels [6].

Even at physiological doses, some women convert enough testosterone to DHT to push susceptible follicles from anagen into catagen. The ADORE trial (N=814) evaluating 1% testosterone cream found that unwanted hair growth (hirsutism) occurred in about 5% of participants, but scalp hair thinning was reported in fewer than 2% [7]. That 2% is not trivial if you are in it. Risk factors include a family history of female pattern hair loss, elevated baseline free testosterone, and concurrent use of androgenic progestins.

Dr. Susan Davis, the lead author of the global consensus statement, has noted: "Testosterone therapy in women should use formulations approved for women and target the premenopausal physiological range. Supraphysiological dosing, including off-label use of male preparations, carries unnecessary androgenic side effects" [6].

Telogen Effluvium at HRT Initiation: A Temporary Problem

Starting any new hormone regimen can trigger a burst of telogen effluvium, a non-scarring, diffuse shed. The body responds to the shift in hormonal milieu by pushing a cohort of follicles from anagen into telogen simultaneously. This typically becomes visible 2 to 3 months after initiation and resolves on its own within 3 to 6 months [8].

The shed can be alarming. Women may lose 200 to 300 hairs per day, compared to a normal baseline of 50 to 100. It does not indicate permanent damage. The key distinction is pattern: telogen effluvium thins diffusely across the entire scalp, while androgenetic alopecia widens the central part and spares the occipital region. A pull test (gentle traction on a bundle of 40 to 60 hairs) yielding more than 10% telogen hairs confirms active shedding [9].

If you are 4 months into a new HRT regimen and the shedding has not slowed, the cause may be androgenic rather than adaptive. That distinction changes management.

Identifying Whether Your HRT Is the Cause

Hair loss is multifactorial. Before attributing thinning to HRT, other causes need exclusion. Thyroid dysfunction, iron deficiency (ferritin <40 ng/mL), vitamin D insufficiency, and chronic telogen effluvium from stress or illness all mimic HRT-related shedding [10].

A focused workup includes:

• TSH and free T4 to rule out hypothyroidism or hyperthyroidism
• Serum ferritin (target above 40 ng/mL for hair; some dermatologists aim for above 70 ng/mL)
• Total and free testosterone, DHEA-S to assess androgen excess
• SHBG (low levels amplify free androgen exposure)
• 25-hydroxyvitamin D (deficiency below 20 ng/mL is associated with diffuse hair loss)

A 2019 review in Dermatologic Therapy reported that 72% of women presenting with diffuse hair loss had at least one nutritional deficiency, and correcting the deficiency alone improved shedding in a significant proportion before any hormonal adjustment was needed [11].

Timeline matters. Hair loss that began before HRT initiation points to menopausal androgen shift or another etiology. Hair loss that started 2 to 6 months after beginning or changing an HRT regimen implicates the regimen itself, especially if the progestogen component is androgenic.

Switching Regimens: What the Evidence Supports

When an androgenic progestogen is the suspected driver, the first-line intervention is straightforward. Switch to a non-androgenic alternative.

Preferred progestogens for hair-sensitive women:

• Micronized progesterone (100 to 200 mg oral or vaginal)
• Dydrogesterone (10 mg oral)
• The levonorgestrel IUD (Mirena) delivers progestogen locally to the uterus with minimal systemic absorption, and a Cochrane review found it effective for endometrial protection during estrogen therapy [12]

Progestogens to avoid if hair is a concern:

• Norethisterone (norethindrone)
• Levonorgestrel (oral formulations)
• Medroxyprogesterone acetate at high doses

The route of estrogen delivery also matters. Transdermal estradiol (patches, gels) avoids first-pass hepatic metabolism and produces a more stable estradiol-to-estrone ratio. Oral estrogens increase SHBG production, which binds free testosterone and may actually be protective for hair. But oral estrogens carry higher thrombotic risk [13]. The risk-benefit calculation depends on the whole clinical picture, not hair alone.

The 2022 Hormone Therapy Position Statement of The Menopause Society (formerly NAMS) states: "The selection of type, dose, formulation, route of administration, and duration of use should be individualized based on the woman's symptoms, health history, and preferences" [14]. Hair response fits squarely into that individualization framework.

Anti-Androgen Add-Ons for Persistent Thinning

If switching the progestogen is insufficient, anti-androgen medications can be added. These are off-label for hair loss in women but supported by clinical data.

Spironolactone (50 to 200 mg/day) is the most commonly prescribed anti-androgen for female pattern hair loss in the United States. It blocks the androgen receptor and inhibits 5-alpha reductase. A retrospective study of 166 women treated with spironolactone for androgenetic alopecia reported that 74.3% showed clinical improvement at 12 months, with the best responses at doses of 150 to 200 mg [15]. Potassium monitoring is required. Spironolactone is contraindicated in pregnancy.

Topical minoxidil (2% or 5%) remains a first-line option regardless of whether the hair loss is HRT-related or idiopathic. It works by prolonging anagen and increasing follicular blood flow, independent of hormonal mechanisms. A randomized trial of 5% minoxidil versus 2% in women found that the 5% concentration produced superior regrowth at 48 weeks, though facial hypertrichosis was more common [16].

Finasteride and dutasteride are 5-alpha reductase inhibitors used in male pattern hair loss. Their use in postmenopausal women is less established, but a randomized controlled trial of finasteride 1 mg/day in 137 postmenopausal women with androgenetic alopecia showed no significant benefit over placebo at 12 months [17]. Dutasteride 0.5 mg has shown more promise in small series, but data remain limited. Both are teratogenic and absolutely contraindicated in women of childbearing potential.

The Estrogen-Protective Effect: When HRT Helps Hair

For many women, starting estrogen-containing HRT improves hair. This deserves emphasis because the question "can HRT cause hair loss" may prevent women from accessing a therapy that would actually help their thinning.

The mechanism is direct. Estradiol upregulates aromatase in hair follicle keratinocytes, converting local testosterone to estradiol at the follicle level [18]. It also extends anagen duration through estrogen receptor beta signaling in dermal papilla cells. Women who start transdermal estradiol for vasomotor symptoms and report "my hair feels thicker" at 6 months are describing a real biological effect.

A prospective observational study of 75 postmenopausal women starting transdermal estradiol with micronized progesterone found that hair density measured by phototrichogram increased by 13% at 12 months compared to baseline [19]. The improvement was most pronounced in women with the lowest baseline estradiol levels.

The clinical takeaway is binary. If your HRT includes a non-androgenic progestogen and your estradiol levels are optimized (typically 50 to 150 pg/mL on transdermal therapy), you are more likely to gain hair than lose it.

A Practical Decision Framework

If you are on HRT and noticing hair changes, this sequence covers the most common scenarios:

1. Timeline check. Did shedding start within 2 to 4 months of initiating or changing HRT? If yes, wait until the 6-month mark before intervening. Early telogen effluvium usually self-corrects.

2. Lab workup. Check TSH, ferritin, vitamin D, total and free testosterone, DHEA-S, and SHBG. Correct deficiencies first.

3. Progestogen audit. If you are taking norethisterone, levonorgestrel, or high-dose medroxyprogesterone acetate, discuss switching to micronized progesterone or dydrogesterone with your prescriber.

4. Testosterone review. If you are using testosterone therapy, confirm your free testosterone is within the premenopausal physiological range (typically <2.0 ng/dL free testosterone). Supraphysiological levels are the most correctable cause of HRT-related hair loss.

5. Add topical minoxidil 5% if shedding persists beyond 6 months despite regimen optimization. Results take 4 to 6 months to become visible.

6. Consider spironolactone 100 to 200 mg if pattern thinning is present (widened part, frontal recession) and androgenetic alopecia is confirmed clinically or by biopsy.

Women on HRT who address hair loss early, within the first year of noticing changes, have the best outcomes. Follicular miniaturization is progressive but partially reversible if intervention begins before terminal hair count drops below 50% of baseline density.